235 related articles for article (PubMed ID: 11594685)
1. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
2. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents.
Scozzafava A; Mastrolorenzo A; Supuran CT
J Enzyme Inhib Med Chem; 2002 Apr; 17(2):69-76. PubMed ID: 12420752
[TBL] [Abstract][Full Text] [Related]
3. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
4. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
[TBL] [Abstract][Full Text] [Related]
5. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
Kanbara K; Fujii N; Nakashima H
Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
[TBL] [Abstract][Full Text] [Related]
6. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
8. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.
Doranz BJ; Grovit-Ferbas K; Sharron MP; Mao SH; Goetz MB; Daar ES; Doms RW; O'Brien WA
J Exp Med; 1997 Oct; 186(8):1395-400. PubMed ID: 9334380
[TBL] [Abstract][Full Text] [Related]
10. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
12. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
[TBL] [Abstract][Full Text] [Related]
13. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.
Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Croce F; Herrmann SH; Offord RE; Galli M; Hirsch MS
J Virol; 2000 Oct; 74(19):9328-32. PubMed ID: 10982382
[TBL] [Abstract][Full Text] [Related]
14. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of fusion inhibitors in HIV infection.
De Clercq E
Drugs R D; 1999 Nov; 2(5):321-31. PubMed ID: 10728472
[TBL] [Abstract][Full Text] [Related]
16. Safe use of the CXCR4 inhibitor ALX40-4C in humans.
Doranz BJ; Filion LG; Diaz-Mitoma F; Sitar DS; Sahai J; Baribaud F; Orsini MJ; Benovic JL; Cameron W; Doms RW
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):475-86. PubMed ID: 11350661
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
[TBL] [Abstract][Full Text] [Related]
19. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
[TBL] [Abstract][Full Text] [Related]
20. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]